FibroBiologics, Inc. (FBLG)
| Market Cap | 29.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.67M |
| Shares Out | 38.26M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404,379 |
| Open | 0.8400 |
| Previous Close | 0.8100 |
| Day's Range | 0.7700 - 0.8500 |
| 52-Week Range | 0.7626 - 13.5900 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 13.00 (+1,559.22%) |
| Earnings Date | May 14, 2025 |
About FBLG
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for FBLG stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 1,559.22% from the latest price.
News
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the develo...
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third...
FibroBiologics Presenting at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the deve...
FibroBiologics Presents at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the deve...
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of t...
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology Located in Houston, Texas, the new facility allow...
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of t...
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing
FibroBiologics Announces 2025 Annual Meeting of Stockholders
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers Master cell bank to be used in manufacturing of CYWC628 drug product to...
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics Announces $25 Million Financing
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeu...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testi...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the develo...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care program...